Investigational New Drugs,volume 32,issue 2  (04-2014)

Period of time: 2014年2期

Publisher: Springer Publishing Company

Founded in: 1983

Total resources: 32

ISSN: 0167-6997

Subject: R9 Pharmacy

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Investigational New Drugs,volume 32,issue 2

Menu

Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor

By King Constance,Diaz Henry,Barnard Darlene,Barda David,Clawson David,Blosser Wayne,Cox Karen,Guo Sherry,Marshall Mark in (2014)

Investigational New Drugs,volume 32,issue 2 , Vol. 32, Iss. 2, 2014-04 , pp. 213-226

Springer Publishing Company

Abstract Access to resources Recommend Favorite

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

By Sonpavde Guru,Wang Mingjun,Peterson Leif,Wang Helen,Joe Teresa,Mims Martha,Kadmon Dov,Ittmann Michael,Wheeler Thomas,Gee Adrian,Wang Rong-Fu,Hayes Teresa in (2014)

Investigational New Drugs,volume 32,issue 2 , Vol. 32, Iss. 2, 2014-04 , pp. 235-242

Springer Publishing Company

Abstract Access to resources Recommend Favorite

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

By Richter Suzanne,Bedard Philippe,Chen Eric,Clarke Blaise,Tran Ben,Hotte Sebastien,Stathis Anastasios,Hirte Hal,Razak Albiruni,Reedijk Michael,Chen Zhuo,Cohen Brenda,Zhang Wen-Jiang,Wang Lisa,Ivy S.,Moore Malcolm,Oza Amit,Siu Lillian,McWhirter Elaine in (2014)

Investigational New Drugs,volume 32,issue 2 , Vol. 32, Iss. 2, 2014-04 , pp. 243-249

Springer Publishing Company

Abstract Access to resources Recommend Favorite

Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer

By Boku Narikazu,Muro Kei,Machida Nozomu,Hashigaki Satoshi,Kimura Nobuyuki,Suzuki Mie,Lechuga Mariajose,Miyata Yoshinori in (2014)

Investigational New Drugs,volume 32,issue 2 , Vol. 32, Iss. 2, 2014-04 , pp. 261-270

Springer Publishing Company

Abstract Access to resources Recommend Favorite

Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer

By Yoo Changhoon,Ryu Min-Hee,Na Young-Soon,Ryoo Baek-Yeol,Lee Chae-Won,Maeng Jeheon,Kim Se-Yeon,Koo Dong,Park Inkeun,Kang Yoon-Koo in (2014)

Investigational New Drugs,volume 32,issue 2 , Vol. 32, Iss. 2, 2014-04 , pp. 271-278

Springer Publishing Company

Abstract Access to resources Recommend Favorite

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

By Ganesan Prasanth,Piha-Paul Sarina,Naing Aung,Falchook Gerald,Wheler Jennifer,Fu Siqing,Hong David,Kurzrock Razelle,Janku Filip,Laday Shell,Bedikian Agop,Kies Merrill,Wolff Robert,Tsimberidou Apostolia in (2014)

Investigational New Drugs,volume 32,issue 2 , Vol. 32, Iss. 2, 2014-04 , pp. 279-286

Springer Publishing Company

Abstract Access to resources Recommend Favorite

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer

By Schelman William,Mohammed Tabraiz,Traynor Anne,Kolesar Jill,Marnocha Rebecca,Eickhoff Jens,Keppen Michael,Alberti Dona,Wilding George,Takebe Naoko,Liu Glenn in (2014)

Investigational New Drugs,volume 32,issue 2 , Vol. 32, Iss. 2, 2014-04 , pp. 295-302

Springer Publishing Company

Abstract Access to resources Recommend Favorite